Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Acquired resistance to osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer occurs through on-target mutations or bypass activation of alternative pathways. The longitudinal molecular evolution of a tumor across successive lines of therapy is rarely captured by repeat biopsy. We report a 68-year-old never-smoking woman with EGFR exon 19 deletion lung adenocarcinoma.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
